(HIMS) Hims Hers Health - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 5.497m USD | Total Return: -50.1% in 12m
Avg Turnover: 460M
Qual. Beats: -1
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
High Debt/EBITDA (5.4) with thin interest coverage (0.5)
Interest Coverage Ratio 0.5 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' 0.95 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Hims & Hers Health, Inc. operates a direct-to-consumer telehealth platform connecting patients with licensed healthcare providers across North America and Europe. The company specializes in personalized prescription treatments, over-the-counter products, and diagnostic testing primarily focused on hair care, sexual health, skincare, mental health, and weight loss.
The business model relies on a recurring subscription framework, which is common in the digital health sector to increase customer lifetime value and reduce friction in chronic condition management. By integrating medical consultations with a proprietary pharmacy fulfillment network, the company bypasses traditional brick-and-mortar healthcare bottlenecks.
Investors looking for deeper financial metrics on this platform should consult ValueRay for further data. The company distributes its branded wellness products through its internal mobile application as well as strategic retail partnerships to diversify its acquisition channels.
- Compounded GLP-1 weight loss drug expansion drives rapid top-line revenue growth
- Increasing marketing spend efficiency and subscriber retention levels improve operating margins
- FDA regulatory changes regarding pharmacy compounding impact core weight loss product availability
- Subscription-based recurring revenue model provides high predictability for future cash flows
- Expansion into personalized multi-condition treatments broadens total addressable market and average order value
| Net Income: -13.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -23.18 > 1.0 |
| NWC/Revenue: 18.00% < 20% (prev 9.34%; Δ 8.66% < -1%) |
| CFO/TA 0.13 > 3% & CFO 283.7m > Net Income -13.2m |
| Net Debt (539.1m) to EBITDA (99.8m): 5.40 < 3 |
| Current Ratio: 1.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (228.4m) vs 12m ago -7.40% < -2% |
| Gross Margin: 67.64% > 18% (prev 0.77%; Δ 6.69k% > 0.5%) |
| Asset Turnover: 150.0% > 50% (prev 200.1%; Δ -50.06% > 0%) |
| Interest Coverage Ratio: 0.45 > 6 (EBITDA TTM 99.8m / Interest Expense TTM 69.8m) |
| A: 0.19 (Total Current Assets 1.05b - Total Current Liabilities 618.8m) / Total Assets 2.27b |
| B: -0.09 (Retained Earnings -205.9m / Total Assets 2.27b) |
| C: 0.02 (EBIT TTM 31.7m / Avg Total Assets 1.58b) |
| D: -0.12 (Book Value of Equity -210.3m / Total Liabilities 1.82b) |
| Altman-Z'' = 0.95 = BB |
| DSRI: 16.22 (Receivables 149.6m/6.94m, Revenue 2.37b/1.78b) |
| GMI: 1.14 (GM 67.64% / 77.04%) |
| AQI: 1.29 (AQ_t 0.33 / AQ_t-1 0.25) |
| SGI: 1.33 (Revenue 2.37b / 1.78b) |
| TATA: -0.13 (NI -13.2m - CFO 283.7m) / TA 2.27b) |
| Beneish M = 9.90 (Cap -4..+1) = D |
As of May 30, 2026, the stock is trading at USD 26.15 with a total of 20,620,217 shares traded.
Over the past week, the price has changed by +8.91%,
over one month by -0.68%,
over three months by +80.10% and
over the past year by -50.10%.
Hims Hers Health has received a consensus analysts rating of 3.46. Therefore, it is recommended to hold HIMS.
- StrongBuy: 4
- Buy: 1
- Hold: 6
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 26.8 | 2.6% |
P/E Forward = 58.8235
P/S = 2.3197
P/B = 12.3208
P/EG = 2.1549
Revenue TTM = 2.37b USD
EBIT TTM = 31.7m USD
EBITDA TTM = 99.8m USD
Long Term Debt = 974.1m USD (from longTermDebt, last quarter)
Short Term Debt = 5.58m USD (from shortTermDebt, last quarter)
Debt = 1.29b USD (from shortLongTermDebtTotal, last quarter) + Leases 157.9m
Net Debt = 539.1m USD (calculated: Debt 1.29b - CCE 750.9m)
Enterprise Value = 6.04b USD (5.50b + Debt 1.29b - CCE 750.9m)
Interest Coverage Ratio = 0.45 (Ebit TTM 31.7m / Interest Expense TTM 69.8m)
EV/FCF = 79.59x (Enterprise Value 6.04b / FCF TTM 75.8m)
FCF Yield = 1.26% (FCF TTM 75.8m / Enterprise Value 6.04b)
FCF Margin = 3.20% (FCF TTM 75.8m / Revenue TTM 2.37b)
Net Margin = -0.56% (Net Income TTM -13.2m / Revenue TTM 2.37b)
Gross Margin = 67.64% ((Revenue TTM 2.37b - Cost of Revenue TTM 766.8m) / Revenue TTM)
Gross Margin QoQ = 49.38% (prev 71.94%)
Tobins Q-Ratio = 2.66 (Enterprise Value 6.04b / Total Assets 2.27b)
Interest Expense / Debt = 5.41% (Interest Expense 69.8m / Debt 1.29b)
Taxrate = 21.0% (US default 21%)
NOPAT = 25.0m (EBIT 31.7m * (1 - 21.00%))
Current Ratio = 1.69 (Total Current Assets 1.05b / Total Current Liabilities 618.8m)
Debt / Equity = 2.89 (Debt 1.29b / totalStockholderEquity, last quarter 446.2m)
Debt / EBITDA = 5.40 (Net Debt 539.1m / EBITDA 99.8m)
Debt / FCF = 7.11 (Net Debt 539.1m / FCF TTM 75.8m)
Total Stockholder Equity = 532.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.84% (Net Income -13.2m / Total Assets 2.27b)
RoE = -1.79% (Net Income TTM -13.2m / Total Stockholder Equity 738.6m)
RoCE = 1.85% (EBIT 31.7m / Capital Employed (Equity 738.6m + L.T.Debt 974.1m))
RoIC = 2.47% (NOPAT 25.0m / Invested Capital 1.01b)
WACC = 14.27% (E(5.50b)/V(6.79b) * Re(16.62%) + D(1.29b)/V(6.79b) * Rd(5.41%) * (1-Tc(0.21)))
Discount Rate = 16.62% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 51.11 | Cagr: 3.85%
[DCF] Terminal Value 54.40% ; FCFF base≈140.1m ; Y1≈122.9m ; Y5≈99.3m
[DCF] Fair Price = 1.24 (EV 815.2m - Net Debt 539.1m = Equity 276.1m / Shares 223.1m; r=14.27% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.97 | # QB: -1
Revenue Correlation: 99.08 | Revenue CAGR: 63.05% | SUE: -0.54 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.05 | Chg30d=-145.82% | Revisions=-67% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.12 | Chg30d=-38.46% | Revisions=-50% | Analysts=10
EPS current Year (2026-12-31): EPS=-0.12 | Chg30d=-122.38% | Revisions=-64% | GrowthEPS=-124.2% | GrowthRev=+22.7%
EPS next Year (2027-12-31): EPS=0.52 | Chg30d=-23.08% | Revisions=-50% | GrowthEPS=+518.8% | GrowthRev=+17.2%
[Analyst] Revisions Ratio: -67%